RESEARCH USE ONLY
Larger volumes? Bulk and wholesale pricing is available on request.
Retatrutide 15mg represents a high-purity research peptide in lyophilized form which can be used in the laboratory to conduct controlled experiments. Being a tri-receptor agonist, the Retatrutide compound is studied in terms of its activity on the GIP, GLP-1 and glucagon receptor pathways.
The 15mg vial represents an average amount for research settings where there is a need for greater amounts than in smaller vials.
Retatrutide has received considerable attention owing to its unique receptor-binding characteristics. As compared to other drugs that are designed with a view to targeting a specific receptor, Retatrutide functions as an agonist on three metabolic receptors, namely glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon.
The 15mg formulation is an ideal medium-sized drug formulation for laboratories to conduct experiments in case a small bottle does not suffice and at the same time there is no need for a larger formulation.
The 15mg format sits between lower-quantity and larger research vials, making it a flexible option for laboratories conducting ongoing experimental work.
It may be particularly useful when a study requires multiple analytical procedures or when researchers want sufficient material from the same batch for a series of related experiments.
Selecting an appropriate vial quantity can also help laboratories manage research materials more efficiently while reducing unnecessary handling of larger quantities.
Retatrutide is commonly described in scientific literature as a triple agonist because its molecular design targets three receptor pathways.
GIP receptors form part of the incretin signalling system and are investigated extensively in metabolic research.
GLP-1 receptors are another important area of metabolic and endocrine research.
Glucagon receptors contribute an additional signalling pathway that differentiates Retatrutide’s research profile from compounds targeting GLP-1 alone or combined GLP-1/GIP pathways.
Studying these pathways simultaneously allows researchers to investigate the biological effects associated with multi-receptor signalling under controlled experimental conditions.
Purity is an important consideration when selecting peptides for laboratory investigation. This Retatrutide 15mg product is specified at 99%+ purity, providing researchers with clearly defined material for analytical and experimental applications.
Relevant analytical documentation should always be reviewed alongside the physical product. Where provided, the Certificate of Analysis (COA) contains information associated with the specific production batch.
Researchers should rely on batch-specific documentation rather than assuming that results obtained for one batch apply universally to every vial.
Research reproducibility depends partly on knowing exactly which material has been used during an experiment. For this reason, batch identification and analytical documentation are important elements of peptide research.
Where available, documentation accompanying Retatrutide 15mg can provide researchers with information concerning product identity, purity and the analytical methods applied to the relevant batch.
Laboratories should maintain appropriate records of batch numbers and associated documentation as part of their normal research procedures.
Independent third-party analysis for the current batch. Verify identity and purity before use.
Orders placed before 15:00 GMT on a working day are dispatched the same day from the United Kingdom in temperature-conscious, discreet packaging. Tracked UK delivery typically arrives within 1–2 working days; international timelines vary by destination and customs.
Retatrutide 15mg is a research peptide containing 15mg of Retatrutide in a sealed laboratory vial. It is supplied as a lyophilised powder and is intended exclusively for controlled research applications.
Retatrutide is described as a triple receptor agonist because it demonstrates activity at the GIP, GLP-1 and glucagon receptors. This multi-receptor profile is one of the main reasons the compound is being investigated scientifically.
This product is specified at 99%+ purity. Researchers should also consult the relevant batch documentation or Certificate of Analysis for analytical information associated with the supplied material.
The primary difference is the quantity of Retatrutide supplied in each vial. A 15mg vial contains three times the total peptide material of a 5mg vial. The appropriate quantity depends on the requirements of the laboratory research programme.
The unopened lyophilised material should be stored according to the conditions specified on its label and accompanying documentation. Researchers should protect laboratory peptides from inappropriate exposure to heat, moisture and direct light.
Retatrutide remains an investigational compound and should not be represented as an authorised UK medicine. Research-grade Retatrutide products are intended for laboratory investigation rather than therapeutic use.
Disclaimer: Retatrutide 15mg is supplied strictly for laboratory research purposes. It is not intended for human or veterinary consumption and must not be used to diagnose, treat, cure or prevent any medical condition.